BMY:NYE-Bristol-Myers Squibb Company

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 59.92

Change

-2.89 (-4.60)%

Market Cap

USD 98.07B

Volume

0.01B

Yahoo Analyst Target

USD 63.86 (6.58%)

STA Analyst Target

USD 63.97 (6.75%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Bristol-Myers Squibb Co is a biopharmaceutical company. It discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.10 (+0.75%)

USD 394.54B
PFE Pfizer Inc.

+0.06 (+0.16%)

USD 218.16B
NVS Novartis AG

+0.08 (+0.09%)

USD 203.20B
MRK Merck & Company Inc. (new)

+3.41 (+5.81%)

USD 169.11B
ABBV AbbVie Inc.

+2.15 (+2.14%)

USD 163.62B
SNY Sanofi American Depositary Sha..

+0.13 (+0.29%)

USD 113.03B
ABT Abbott Laboratories

-0.40 (-0.68%)

USD 101.72B
GSK GlaxoSmithKline PLC

+0.42 (+1.12%)

USD 94.00B
LLY Eli Lilly and Company

-1.69 (-1.94%)

USD 93.91B
AZN Astrazeneca PLC

-0.66 (-1.85%)

USD 88.61B

ETFs Containing BMY

IHE iShares U.S. Pharmaceutic.. 6.31 % 0.44 %

-0.97 (-1.05%)

USD 0.57B
PJP PowerShares Dynamic Pharm.. 4.84 % 0.56 %

-0.32 (-1.05%)

USD 0.66B
XPH SPDR S&P Pharmaceuticals 4.58 % 0.35 %

-0.45 (-1.05%)

USD 0.41B
FTXH First Trust Nasdaq Pharma.. 3.76 % 0.60 %

-0.24 (-1.05%)

USD 2.22M
CNCR Loncar Cancer Immunothera.. 3.30 % 0.79 %

-0.67 (-1.05%)

N/A
XLV SPDR Select Sector Fund -.. 3.25 % 0.14 %

+0.43 (+-1.05%)

USD 17.56B
IYH iShares U.S. Healthcare 3.03 % 0.44 %

+0.62 (+-1.05%)

USD 2.04B
VHT Vanguard Health Care 2.83 % 0.10 %

+0.25 (+-1.05%)

USD 7.51B
FHLC Fidelity MSCI Health Care.. 2.75 % 0.08 %

+0.09 (+-1.05%)

USD 0.97B
FDRR Fidelity Dividend ETF for.. 1.81 % 0.29 %

-0.10 (-1.05%)

USD 0.25B
PILL Direxion Daily Pharmaceut.. 1.75 % 0.00 %

-0.33 (-1.05%)

USD 3.19M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.22% 4% F 15% F
Dividend Return 0.65% 67% D+ 61% D-
Total Return -1.57% 4% F 18% F
Trailing 12 Months  
Capital Gain 6.58% 39% F 50% F
Dividend Return 2.79% 47% F 44% F
Total Return 9.37% 39% F 46% F
Trailing 5 Years  
Capital Gain 74.54% 67% D+ 74% C
Dividend Return 20.68% 67% D+ 61% D-
Total Return 95.22% 72% C- 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.47% 61% D- 69% D+
Dividend Return 11.14% 57% F 70% C-
Total Return 2.67% 41% F 51% F
Risk Return Profile  
Volatility (Standard Deviation) 18.95% 57% F 39% F
Risk Adjusted Return 58.79% 70% C- 54% F
Market Capitalization 93.95B 68% D+ 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.32 52% F 35% F
Price/Book Ratio 7.86 17% F 10% F
Price / Cash Flow Ratio 6.55 13% F 13% F
Price/Free Cash Flow Ratio 23.32 39% F 29% F
Management Effectiveness  
Return on Equity 28.16% 78% C+ 90% A-
Return on Invested Capital 18.66% 74% C 84% B
Return on Assets 12.62% 91% A- 93% A
Debt to Equity Ratio 53.25% 64% D 63% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.